Medigene AG
MDG1
Classement en actions
#35302
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Prix de l'action
$0.14942078
Dernière synchronisation: 2025-05-15
Capitalisation boursière
$3.86M
Changement (1 jour)
0.10%
Changement (1 an)
47.84%
Pays
DE
Échange Medigene AG (MDG1)
Catégorie
Healthcare
Ratio P/S pour Medigene AG (MDG1)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Medigene AG, le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Medigene AG de 2026 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
